Effector Therape -CW27EFTRWPreferred / convertible
13F holders, Q1 2024 (March 31)12holders
$0.14avg. 13F price*
At the end of Q1 2024, 12 institutions reported holding Effector Therape -CW27 (EFTRW) in their 13F filings. The largest holders were Aristeia Capital, L.L.C. ($183K), Goldman Sachs Group Inc. ($85K) and Whitebox Advisors LLC ($40K).
- Company
- Effector Therape -CW27
- CUSIP
- 28202V116
- Latest filing quarter
- Q3 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $2K |
| Exits | 1 | $4K |
Ownership 12 holders
| Aristeia Capital, L.L.C. | — | Reduce -10.7% | 1,333,446 | $183K |
| Goldman Sachs Group Inc. | — | No change | 630,539 | $85K |
| Whitebox Advisors LLC | — | No change | 298,145 | $40K |
| MMCAP International Inc. SPC | — | No change | 145,941 | $20K |
| Parallel Advisors, LLC | — | No change | 64,166 | $9K |
| III Capital Management | — | No change | 41,795 | $6K |
| TENOR CAPITAL MANAGEMENT Co., L.P. | — | No change | 33,333 | $5K |
| Susquehanna International Group, LLP | — | New | 16,794 | $2K |
| Wolverine Asset Management LLC | — | Reduce -44.3% | 9,829 | $1K |
| UBS Group AG | — | Reduce -55.1% | 644 | $87 |
| Pineridge Advisors LLC | — | No change | 33 | $4 |
| Tower Research Capital LLC (TRC) | — | No change | 23 | $3 |
"% of holder's portfolio" is EFTRW's weight in each manager's 13F, not the share of Effector Therape -CW27 the manager owns.